Neogenomics (NEO) Enterprise Value (2010 - 2026)

Neogenomics (NEO) has reported Enterprise Value for 17 consecutive years, with -$146.1 million the latest figure, recorded in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$146.1 million, up 59.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$146.1 million (up 59.19% YoY), and the FY2025 annual result was -$159.6 million, up 58.74% from the prior year.
• Enterprise Value was -$146.1 million for Q1 2026 at Neogenomics, up from -$159.6 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$146.1 million in Q1 2026 and troughed at -$481.4 million in Q1 2022.
• Average Enterprise Value over 5 years is -$353.7 million, with a median of -$387.9 million recorded in 2024.
• Year-over-year, Enterprise Value increased 3.59% in 2024 and soared 59.19% in 2026.
• Over 5 years, Enterprise Value stood at -$438.0 million in 2022, then grew by 5.2% to -$415.2 million in 2023, then advanced by 6.83% to -$386.8 million in 2024, then surged by 58.74% to -$159.6 million in 2025, then increased by 8.44% to -$146.1 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$146.1 million in Q1 2026, -$159.6 million in Q4 2025, and -$164.1 million in Q3 2025.